BTKi, venetoclax, obinutuzumab: what is the ideal combination?
Crossref DOI link: https://doi.org/10.1007/s12254-021-00776-4
Published Online: 2021-12-20
Published Print: 2022-02
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Heintel, Daniel
Text and Data Mining valid from 2021-12-20
Version of Record valid from 2021-12-20
Article History
Received: 30 August 2021
Accepted: 8 November 2021
First Online: 20 December 2021
Conflict of interest
: D. Heintel declares that he has no competing interests.